Gemcitabine, vinorelbine, doxorubicin salvage for Hodgkin’s – pro
Gemcitabine and vinorelbine are somewhat effective but toxic when few options remain, but more investigation is needed.
The optimum therapy for patients with relapsed or refractory aggressive HOdgkin’s not qualifying for high-dose chemotherapy is not known. Hodgkin’s lymphoma patients who relapse or do not respond to primary treatment require an adequate salvage therapy. HDCT followed by ASCT is the treatment of choice for this group of patients. Only a few relapsed patients can be cured by conventional chemotherapy and/or RT.
Combinations of gemcitabine and vinorelbine ahve been studied; recently Doxorubicin has been added and studied for salvage. GVD is a well-tolerated, active regimen for relapsed HL with results similar to those reported for more toxic regimens. High RRs in patients in whom prior transplant failed confirms this regimen’s activity even in heavily pretreated patients.
A. Spencer, K. Reed and C. Arthur. (2007) Pilot study of an outpatient-based approach for advanced lymphoma using vinorelbine, gemcitabine and filgrastim. Internal Medicine Journal 37:11, 760–766
NL Bartlett , D Niedzwiecki , JL Johnson , JW Friedberg , KB Johnson , K van Besien , AD Zelenetz , BD Cheson , GP Canellos , and For the Cancer Leukemia Group B
Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin’s lymphoma: CALGB 59804 Ann Oncol 18: 1071-1079, 2007